Abstract PS7-78: Trends in BRCA testing among patients diagnosed with breast cancer -a retrospective analysis of a United States commercial claims database from the PRIOR-1 study

Abstract

Background The use of BRCA testing to guide the course of breast cancer treatment has evolved in the last 5 years; however, little is known about the use of BRCA testing in a real-world setting. This study assessed the trend in prevalence of BRCA testing and sociodemographic and clinical predictors of receiving a BRCA test among newly diagnosed patients with breast cancer. Methods This was a retrospective study conducted using the Optum Clinformatics Datamart database. Patients newly diagnosed with breast cancer, continuously enrolled in a health plan for ≥6 months before and after diagnosis were included in the study. Claims for BRCA testing were identified after diagnosis using HCPCS, ICD-9/10 procedure, and LOINC codes. The prevalence of BRCA testing was calculated for patients diagnosed in each year from 2012-2017. Multivariable logistic regression was used to assess predictors of BRCA testing controlling for sociodemographic and clinical factors. Results From a total of 81,774 breast cancer patients included, 13,529 (16.5%) received a BRCA test after diagnosis. The prevalence of BRCA testing increased from 1,721 (11.5%) in 2012 to 2,384 (17.1%) in 2013 and remained stable over time until 2017 [2,191, (18.5%)]. Of patients receiving a BRCA test, 11,688 (86%) were tested within 1 year of diagnosis. The median time to receive a BRCA test from diagnosis was 29 days (mean: 172.7 days). Results from logistic regression indicated that diagnosis at a younger age (e.g., 18-44 years versus ≥75 years, odds ratio [OR] = 25.3), diagnosis in recent years (e.g., 2017 versus 2012, OR =1.94), having a point of service versus health maintenance organization plan type (OR = 1.10), presence of metastasis (OR = 1.62), and family history of cancer (OR = 4.98) significantly (P<0.05) increased odds for receiving a BRCA test. Female gender (OR = 0.28), living in regions other than West (e.g. South, OR = 0.86), having commercial insurance versus Medicare Advantage (OR = 0.96), Charlson comorbidity index score of ≥3 vs 0 (OR= 0.83) were significantly (P<0.05) associated with lower odds of receiving a BRCA test. Conclusions Prevalence of BRCA testing among breast cancer patients increased initially in 2013 and remained stable over time until 2017. Several demographic and clinical factors were associated with the use of BRCA testing among breast cancer patients. Citation Format: Shelby Corman, Hrishikesh Kale, Pooja Shah, Gboyega Adeboyeje. Trends in BRCA testing among patients diagnosed with breast cancer -a retrospective analysis of a United States commercial claims database from the PRIOR-1 study [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS7-78.

Nanomaterial-based biosensor developing as a route toward in vitro diagnosis of early ovarian cancer

“…In conclusion, nanomaterial-based IVD not only improves our understanding of OC pathology, treatment, but may have a major impact in the field of oncology. Finally, the clinical transformation of more nanomaterials-based biosensors will be realized soon in the field of early OC diagnosis with the advances of tumor biology and nanotechnology [ [128] , [129] , [130] , [131] ]. More effective and reliable nanomaterial-based IVD, with higher sensitivity and accuracy, smaller size, and more economical price, will be developed for clinical testing and even home self-testing.…”